134 related articles for article (PubMed ID: 11902457)
21. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density.
Goldenberg JD; Portugal LG; Wenig BL; Ferrer K; Wu JC; Sabnani J
Head Neck; 1998 Mar; 20(2):152-8. PubMed ID: 9484947
[TBL] [Abstract][Full Text] [Related]
22. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
23. Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors.
Kusaka T; Fukui H; Sano Y; Ueda Y; Chiba T; Fujimori T
J Gastroenterol Hepatol; 2000 Oct; 15(10):1151-7. PubMed ID: 11106095
[TBL] [Abstract][Full Text] [Related]
24. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas.
Rodrigues RF; Roque L; Rosa-Santos J; Cid O; Soares J
Br J Cancer; 2004 Jan; 90(2):492-6. PubMed ID: 14735198
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
27. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid.
Hunt JL; Tometsko M; LiVolsi VA; Swalsky P; Finkelstein SD; Barnes EL
Am J Surg Pathol; 2003 Dec; 27(12):1559-64. PubMed ID: 14657716
[TBL] [Abstract][Full Text] [Related]
28. Lack of p16/CDKN2 alterations in thyroid carcinomas.
Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
[TBL] [Abstract][Full Text] [Related]
29. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
30. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
31. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
32. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
33. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
34. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
35. Sporadic p53 mutations and absence of ras mutations in glioblastomas.
Gömöri E; Dóczi T; Pajor L; Matolcsy A
Acta Neurochir (Wien); 1999; 141(6):593-9. PubMed ID: 10929724
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.
Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA
Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
39. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
[TBL] [Abstract][Full Text] [Related]
40. H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid.
Castro P; Soares P; Gusmão L; Seruca R; Sobrinho-Simões M
Oncogene; 2006 Aug; 25(33):4620-7. PubMed ID: 16532025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
